標(biāo)題: Titlebook: Ciprofloxacin i.v.; Defining Its Role in Christopher Garrard (Intensive Care Director) Conference proceedings 1994 Springer-Verlag Berlin H [打印本頁(yè)] 作者: GERM 時(shí)間: 2025-3-21 19:27
書目名稱Ciprofloxacin i.v.影響因子(影響力)
書目名稱Ciprofloxacin i.v.影響因子(影響力)學(xué)科排名
書目名稱Ciprofloxacin i.v.網(wǎng)絡(luò)公開度
書目名稱Ciprofloxacin i.v.網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Ciprofloxacin i.v.被引頻次
書目名稱Ciprofloxacin i.v.被引頻次學(xué)科排名
書目名稱Ciprofloxacin i.v.年度引用
書目名稱Ciprofloxacin i.v.年度引用學(xué)科排名
書目名稱Ciprofloxacin i.v.讀者反饋
書目名稱Ciprofloxacin i.v.讀者反饋學(xué)科排名
作者: barium-study 時(shí)間: 2025-3-21 20:58 作者: 使乳化 時(shí)間: 2025-3-22 04:10 作者: Fretful 時(shí)間: 2025-3-22 08:09
cacy, safety and therapeutic use of the antibiotic substance Ciprofloxacin. Of special interest for clinicians will be the clinical outcome in patients with nosocomial pneumonia and other infections of the lower respiratory tract.978-3-642-79100-0978-3-642-79098-0作者: 接觸 時(shí)間: 2025-3-22 09:03 作者: foliage 時(shí)間: 2025-3-22 14:54 作者: foliage 時(shí)間: 2025-3-22 17:49
A Survey of Recent Developments,The safety profile of ciprofloxacin has been established in clinical trials since 1983 [1–4]. Postmarketing experience also contributes to this knowledge [5, 6]. Recently two pharmacoepidemiological studies have supported the known safety profile of ciprofloxacin in large outpatient populations [7, 8].作者: thwart 時(shí)間: 2025-3-22 22:26 作者: 終端 時(shí)間: 2025-3-23 01:39
Ciprofloxacin in Neutropenic Host Infection,The most frequent complication of granulocytopenia is infection which, if left untreated, often leads to death. As early as 1966 a retrospective analysis conducted in patients with acute leukemia confirmed that the depth and duration of neutropenia is inversely proportional to the risk of life-threatening infection [1].作者: 舉止粗野的人 時(shí)間: 2025-3-23 09:06 作者: vertebrate 時(shí)間: 2025-3-23 12:56
https://doi.org/10.1007/978-3-642-79098-0antibiotic; antibiotics; infection; infections; oncology; outcome; patients; pharmacodynamics; pharmacology; 作者: GRAVE 時(shí)間: 2025-3-23 17:36
978-3-642-79100-0Springer-Verlag Berlin Heidelberg 1994作者: 莊嚴(yán) 時(shí)間: 2025-3-23 18:16
https://doi.org/10.1007/978-3-030-25350-9e discrepancy between activity against bacteria growing in vitro and in vivo is the growth rate. A characteristic response of bacteria to environmental changes such as growth in an infected focus is a reduction in the growth rate. Slowly growing bacteria generally survive better than those replicati作者: Thrombolysis 時(shí)間: 2025-3-23 23:43
On the African Continental Free Trade Aread phenomena such as the integration of the pharmacological and antimicrobial profiles of drugs became known as pharmacodynamics and is increasingly being applied to the design of dose regimens (MacKenzie and Gould 1993). This is necessary as there often seems to be little or no scientific basis for 作者: 水土 時(shí)間: 2025-3-24 03:43 作者: 煩躁的女人 時(shí)間: 2025-3-24 09:22 作者: 動(dòng)物 時(shí)間: 2025-3-24 11:03 作者: Confound 時(shí)間: 2025-3-24 14:56 作者: 加入 時(shí)間: 2025-3-24 21:23
Joseph Aversa,Tony Hernandez,Sean Dohertyacquired infections and is the most common nosocomial infection encountered by patients in the intensive care unit (ICU), especially in patients requiring mechanical ventilatory support [1]. Nosocomial pneumonia in ventilated patients—referred to by the recently introduced term ventilator-associated作者: Desert 時(shí)間: 2025-3-25 03:10 作者: receptors 時(shí)間: 2025-3-25 07:22 作者: V洗浴 時(shí)間: 2025-3-25 09:48 作者: 時(shí)代錯(cuò)誤 時(shí)間: 2025-3-25 12:24 作者: 營(yíng)養(yǎng) 時(shí)間: 2025-3-25 19:22 作者: –FER 時(shí)間: 2025-3-25 21:08 作者: Asseverate 時(shí)間: 2025-3-26 02:37 作者: Urgency 時(shí)間: 2025-3-26 05:38 作者: 的是兄弟 時(shí)間: 2025-3-26 09:23
Efficacy and Safety of Ciprofloxacin in Various Intravenous Dosages,fections. The German Federal Health Office had specified 750 mg b.i.d. as the maximum dose for oral administration. We found it difficult to understand why, since its bioavailability is approx. 70%–80%; the maximum daily dose of ciprofloxacin for intravenous administration should be limited to 200 m作者: patriarch 時(shí)間: 2025-3-26 14:24
Intravenous Ciprofloxacin Versus Imipenem/ Cilastatin in the Treatment of Severe Pneumonia,acquired infections and is the most common nosocomial infection encountered by patients in the intensive care unit (ICU), especially in patients requiring mechanical ventilatory support [1]. Nosocomial pneumonia in ventilated patients—referred to by the recently introduced term ventilator-associated作者: AMITY 時(shí)間: 2025-3-26 17:38
,Conversion from Intravenous to Oral Ciprofloxacin: Observing the “Like-to-Like” Phenomenon,ften occurring late in the course of therapy. Because of cost-containment pressures the concept of switching to oral agents early in the course of antibiotic therapy is important, and this has become a major goal of antibiotic monitoring programs [1–10]. In several of these programs [1, 6, 8] partic作者: CAPE 時(shí)間: 2025-3-26 21:09 作者: CLOT 時(shí)間: 2025-3-27 03:46
Conference proceedings 1994ty and therapeutic use of the antibiotic substance Ciprofloxacin. Of special interest for clinicians will be the clinical outcome in patients with nosocomial pneumonia and other infections of the lower respiratory tract.作者: Outmoded 時(shí)間: 2025-3-27 06:43
Efficacy and Safety of Ciprofloxacin in Various Intravenous Dosages,g b.i.d. We wished to obtain clinical experience, particularly in severe nosocomial infections caused by resistant organisms, using not only the permitted i.v. standard dose but also higher i.v. doses.作者: 免費(fèi) 時(shí)間: 2025-3-27 11:48
,Conversion from Intravenous to Oral Ciprofloxacin: Observing the “Like-to-Like” Phenomenon,ular attention has been placed on oral fluoroquinolones, for these agents exhibit favorable pharmacokinetic and microbiologic characteristics, have shown efficacy in the treatment of a variety of infectious diseases [1, 11], and can reduce the cost of antibiotic therapy [12–17].作者: 開頭 時(shí)間: 2025-3-27 16:36
Intravenous Ciprofloxacin for the Treatment of Lower Respiratory Tract Infections: Preliminary Resua few days of clinical improvement. Studies so far performed have demonstrated that in various serious infections oral ciprofloxacin can shorten the course of parenteral antibiotics and thus minimize the period of hospitalization and reduce costs [2–6].作者: 斜坡 時(shí)間: 2025-3-27 21:36
Regional Integration in Trade Theoryg b.i.d. We wished to obtain clinical experience, particularly in severe nosocomial infections caused by resistant organisms, using not only the permitted i.v. standard dose but also higher i.v. doses.作者: 雜役 時(shí)間: 2025-3-27 22:08
Joseph Aversa,Tony Hernandez,Sean Dohertyular attention has been placed on oral fluoroquinolones, for these agents exhibit favorable pharmacokinetic and microbiologic characteristics, have shown efficacy in the treatment of a variety of infectious diseases [1, 11], and can reduce the cost of antibiotic therapy [12–17].作者: Arresting 時(shí)間: 2025-3-28 04:25
Jamal Jokar Arsanjani,Ruben López Vázqueza few days of clinical improvement. Studies so far performed have demonstrated that in various serious infections oral ciprofloxacin can shorten the course of parenteral antibiotics and thus minimize the period of hospitalization and reduce costs [2–6].作者: 發(fā)生 時(shí)間: 2025-3-28 06:17 作者: botany 時(shí)間: 2025-3-28 13:44 作者: fiction 時(shí)間: 2025-3-28 16:49 作者: Vulnerable 時(shí)間: 2025-3-28 21:39 作者: 碎片 時(shí)間: 2025-3-29 01:12 作者: 租約 時(shí)間: 2025-3-29 05:27
The Effects of Different Types of Antimicrobial Agents on Plasma Endotoxin Activity in Gram-Negativacterial infection, induces an increased release of lipopolysaccharides in Gram-negative infections [2-4, 10, 11, 13-16, 19, 24, 29, 30-33, 35]. The toxic principle of the lipopolysaccharide, lipid A, which is normally sequestered in the wall of Gram-negative bacteria, is exposed by the antibiotic action.作者: 讓空氣進(jìn)入 時(shí)間: 2025-3-29 07:50 作者: tinnitus 時(shí)間: 2025-3-29 11:41
On the African Continental Free Trade Area the properties of the growth medium, including osmolality and pH, the size of the bacterial inoculum, the initial antibiotic concentration, the exposure time to the antibiotic, and the method of antibiotic removal. Therefore, many comparative studies are necessary to evaluate the PAE of the differe作者: 噴油井 時(shí)間: 2025-3-29 16:05 作者: effrontery 時(shí)間: 2025-3-29 20:38
The Postantibiotic Effect of Ciprofloxacin, the properties of the growth medium, including osmolality and pH, the size of the bacterial inoculum, the initial antibiotic concentration, the exposure time to the antibiotic, and the method of antibiotic removal. Therefore, many comparative studies are necessary to evaluate the PAE of the differe作者: Adrenaline 時(shí)間: 2025-3-30 03:43 作者: COKE 時(shí)間: 2025-3-30 06:53
10樓作者: Pruritus 時(shí)間: 2025-3-30 08:56
10樓
